Abstract
Leukemogenesis requires two classes of mutations, one that promotes proliferation and one that blocks differentiation. The erythroleukemia induced by Friend virus is a multistage disease characterized by an early proliferative stage driven by the interaction of the viral glycoprotein, gp55, with Sf-Stk and the EpoR, and a late block to differentiation resulting from retroviral insertion in the Pu.1 locus. We demonstrate here that activation of Stat3 by Sf-Stk in the early stage of disease is essential for the progression of erythroleukemia in the presence of differentiation signals induced by the EpoR, but is dispensable in the late stages of the disease. Furthermore, we identify Pu.1 as a Stat3 target gene in the early stages of erythroleukemia development. Our results support a model whereby the activation of Stat3 in the early stage of disease plays a pivotal role in regulating differentiation through the upregulation of Pu.1, thus inhibiting differentiation and favoring the expansion of infected erythroblasts and enhancing the pool of progenitors available for the acquisition of additional mutations, including insertional activation of Pu.1, resulting in full leukemic transformation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Afrikanova I, Yeh E, Bartos D, Watowich SS, Longmore GD . (2002). Oncogene cooperativity in Friend erythroleukemia: erythropoietin receptor activation by the env gene of SFFV leads to transcriptional upregulation of PU.1 independent of SFFV proviral insertion. Oncogene 21: 1272–1284.
Chesebro B, Wehrly K, Cloyd M, Britt W, Portis J, Collins J et al. (1981). Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology 112: 131–144.
Choe KS, Radparvar F, Matushansky I, Rekhtman N, Han X, Skoultchi AI . (2003). Reversal of tumorigenicity and the block to differentiation in erythroleukemia cells by GATA-1. Cancer Res 63: 6363–6369.
Constantinescu SN, Keren T, Russ WP, Ubarretxena-Belandia I, Malka Y, Kubatzky KF et al. (2003). The erythropoietin receptor transmembrane domain mediates complex formation with viral anemic and polycythemic gp55 proteins. J Biol Chem 278: 43755–43763.
Fang C, Choi E, Nie L, Li JP . (1998). Role of the transmembrane sequence of spleen focus-forming virus gp55 in erythroleukemogenesis. Virology 252: 46–53.
Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH . (2002). Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene 21: 3562–3570.
Kosmider O, Denis N, Lacout C, Vainchenker W, Dubreuil P, Moreau-Gachelin F . (2005). Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 8: 467–478.
Kuhn R, Schwenk F, Aguet M, Rajewsky K . (1995). Inducible gene targeting in mice. Science 269: 1427–1429.
Mager DL, Mak TW, Bernstein A . (1981). Quantitative colony method for tumorigenic cells transformed by two distinct strains of Friend leukemia virus. Proc Natl Acad Sci USA 78: 1703–1707.
Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G et al. (1996). Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 16: 2453–2463.
Ney PA, D’Andrea AD . (2000). Friend erythroleukemia revisited. Blood 96: 3675–3680.
Ni S, Zhao C, Feng GS, Paulson RF, Correll PH . (2007). A novel Stat3 binding motif in Gab2 mediates transformation of primary hematopoietic cells by the Stk/Ron receptor tyrosine kinase in response to Friend virus infection. Mol Cell Biol 27: 3708–3715.
Panopoulos AD, Bartos D, Zhang L, Watowich SS . (2002). Control of myeloid-specific integrin alpha Mbeta 2 (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1. J Biol Chem 277: 19001–19007.
Papetti M, Skoultchi AI . (2007). Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1. Mol Cancer Res 5: 1053–1062.
Persons DA, Paulson RF, Loyd MR, Herley MT, Bodner SM, Bernstein A et al. (1999). Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet 23: 159–165.
Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H et al. (1999). Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 18: 4657–4668.
Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy DE et al. (2004). Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24: 407–419.
Shimizu R, Kuroha T, Ohneda O, Pan X, Ohneda K, Takahashi S et al. (2004). Leukemogenesis caused by incapacitated GATA-1 function. Mol Cell Biol 24: 10814–10825.
Tambourin PE, Gallien-Lartigue O, Wendling F, Huaulme D . (1973). Erythrocyte production in mice infected by the polycythaemia-inducing Friend virus or by the anaemia-inducing Friedn virus. Br J Haematol 24: 511–524.
Teal HE, Ni S, Xu J, Finkelstein LD, Cheng AM, Paulson RF et al. (2006). GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells. Oncogene 25: 2433–2443.
Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE et al. (2005). Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 65: 939–947.
Yuan ZL, Guan YJ, Chatterjee D, Chin YE . (2005). Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307: 269–273.
Zhang J, Randall MS, Loyd MR, Li W, Schweers RL, Persons DA et al. (2006). Role of erythropoietin receptor signaling in Friend virus-induced erythroblastosis and polycythemia. Blood 107: 73–78.
Zhang X, Darnell Jr JE . (2001). Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J Biol Chem 276: 33576–33581.
Acknowledgements
This work was supported by grant R01 HL066571 from the National Institutes of Health and by a scholar award from the Leukemia and Lymphoma Society to P Hankey.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hegde, S., Ni, S., He, S. et al. Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation. Oncogene 28, 3349–3359 (2009). https://doi.org/10.1038/onc.2009.202
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.202
Keywords
This article is cited by
-
Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression
Cell Communication and Signaling (2021)
-
Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression
Cell Death & Disease (2020)
-
microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia
Oncogene (2016)
-
Staurosporine induces megakaryocytic differentiation through the upregulation of JAK/Stat3 signaling pathway
Annals of Hematology (2011)
-
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
Cell Division (2010)
